3924-22-9

Usage

Uses

Used in Hormone Regulation Research:
11-BETA-HYDROXYANDROSTENEDIOL is used as a research compound for studying its role in the regulation of hormonal balance. It aids in understanding the mechanisms behind hormone-related conditions and diseases.
Used in Endocrine System Studies:
In the field of endocrinology, 11-BETA-HYDROXYANDROSTENEDIOL is utilized as a key chemical for investigating its function within the endocrine system and its implications in various hormone-related disorders.
Used in Biomarker Identification:
11-BETA-HYDROXYANDROSTENEDIOL is employed as a potential biomarker for certain hormone-related disorders, helping in the early detection and diagnosis of conditions such as breast cancer and polycystic ovary syndrome.
Used in Pharmaceutical Development:
This chemical serves as a starting point or intermediate in the development of pharmaceuticals targeting hormone-related conditions and diseases, potentially leading to novel treatments and therapies.
Used in Diagnostic Tools:
11-BETA-HYDROXYANDROSTENEDIOL may be incorporated into diagnostic tools and tests to measure hormone levels and monitor the effectiveness of treatments for hormone-related disorders.

Upstream product

• 382-45-6 adrenosterone 
• 17520-04-6 3-acetoxyandrosta-3,5-diene-11,17-dione 
• 1816-85-9 11β-hydroxytestosterone 

Downstream Products

• 82251-59-0 dehydro-oogoniol 
• 82251-59-0 dehydro-oogoniol 
• 17520-02-4 3β-Hydroxy-androsten-(5)-dion-(11,17) 

Relevant academic research and scientific papers

Raw synthesis and mitochondrial function postischemic mitochondria diseases related to the lack or for use in new compd. 11β-hydroxysteroid

The present invention provides novel compounds of 112-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

Synthesis of dehydro-oogoniol and oogoniol: The adrenosterone route

Dehydro-oogoniol(3β, 11α, 15β,29-tetrahydroxystigmasta-5,24(28)(E)-dien-7-one), a female-activating hormone of the water mold Achlya, has been synthesized from 4-androstene-3,11,17-trione by a series of highly stereoselective reactions. One of these involved 1,4-addition of the magnesium cyanocuprate derivative of 3-(1,3-dioxolan-2-yl)-4-methylpentyl bromide to 3β-hydroxy-15β,16β-epoxy-11-oxo-(17E)-pregna -5, 17(20)-diene 3-tert -butyidimethylsilyl ether. The structure of an intermediate, 3β,11 β,15β-triacetoxy-5-cholesten-24-one, was confirmed by X-ray crystallographic analysis. Oogoniol [(24R)-3β,11α,15β,29-tetrahydroxy-stigmast-5-en-7-one] was synthesized in a similar manner by reaction of the magnesium cyanocuprate of (S)-3-(1-methylethyl)-5-[(tert-butyldimethylsilyl)oxy]pentyl bromide with the above epoxy pregnadiene.

Synthesis of Oogoniol

Oogoniol , a female-activating hormone of Achlya, has been synthesized from 4-androstene-3,11,17-trione.A novel step involved 1,4-addition of the magnesium cyanocuprate derivative of (S)-3-(1-methylethyl)-5-pentyl bromide to 3β-hydroxy-15β,16β-epoxy-11-oxo-(17(20)E)-pregna-5,17(20)-diene 3-tert-butyldimethylsilyl ether.Selective hydrogenation of the resulting Δ16 double bond gave only the stigmastene product with the correct stereochemistry at C15, C17, and C20.